Tagrisso, which targets exon 19 deletions or exon 21 (L858R) mutations, received the approval following a priority review.

FDA has approved Tagrisso for the treatment of adult patients with locally advanced, unresectable NSCLC whose disease has not progressed during or following concurrent or sequential platinum-based ...

Wave Life Sciences Ltd. (NASDAQ:WVE) revealed interim data from the ongoing Phase 2 FORWARD-53 study of WVE-N531 for Duchenne ...

TAGRISSO is indicated for patients with exon 19 deletions or exon 21 (L858R) mutations, as detected by a FDA-approved test. The approval follows a Priority Review by the Food and Drug Administration ...

Osimertinib is now an FDA-approved therapy for stage III NSCLC with EGFR exon 19 deletions or exon 21 L858R mutations that ...

In the phase 2 FORWARD-53 study, the exon-skipping oligonucleotide WVE-N531 showed promising safety and efficacy in boys with Duchenne muscular dystrophy (DMD) who are amenable to exon 53 skipping.

Zipalertinib appeared safe and effective in the treatment of heavily pretreated patients with non-small cell lung cancer ...

Wave’s result is in line with the data that supported accelerated approval of NS Pharma’s exon 53 DMD drug Viltepso. NS ...

The FDA has approved osimertinib (Tagrisso) for locally advanced, unresectable stage III non-small cell lung cancer (NSCLC) ...

BARCELONA, Spain — In a groundbreaking study that could reshape our understanding of cancer, scientists have uncovered a treasure trove of potential new targets for cancer treatment. This discovery ...

Amivantamab plus chemo is now indicated in locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R ...

Johnson & Johnson (JNJ) announced that the U.S. Food and Drug Administration approved RYBREVANT (amivantamab-vmjw) in combination ...